Cargando…

Screening diagnostic markers for acute myeloid leukemia based on bioinformatics analysis

BACKGROUND: An in-depth understanding of the key molecules and associated mechanisms involved in acute myeloid leukemia (AML) carcinogenesis, proliferation, and relapse is critical. This provides a basis for disease screening, early diagnosis, and development of effective treatment strategies and pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Wenting, Liu, Dan, Wang, Guyun, Pan, Yanping, Wang, Shuwen, Tang, Ruimei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273715/
https://www.ncbi.nlm.nih.gov/pubmed/35836534
http://dx.doi.org/10.21037/tcr-22-1257
_version_ 1784745138926387200
author Chen, Wenting
Liu, Dan
Wang, Guyun
Pan, Yanping
Wang, Shuwen
Tang, Ruimei
author_facet Chen, Wenting
Liu, Dan
Wang, Guyun
Pan, Yanping
Wang, Shuwen
Tang, Ruimei
author_sort Chen, Wenting
collection PubMed
description BACKGROUND: An in-depth understanding of the key molecules and associated mechanisms involved in acute myeloid leukemia (AML) carcinogenesis, proliferation, and relapse is critical. This provides a basis for disease screening, early diagnosis, and development of effective treatment strategies and prognosis. METHODS: We downloaded AML transcription data sets from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Differentially expressed genes (DEGs) were screened by R software and limma packages. Gene Ontology (GO) functional enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed on DEGs by public databases. In the DEG set, a random forest algorithm was used to identify characteristic genes of AML. The receiver operator characteristic (ROC) curve was used to evaluate the diagnostic efficacy of selected characteristic genes, which provided clues for the discovery of early diagnostic markers. The Estimate score was calculated using the Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data (ESTIMATE) algorithm. Spearman’s correlation test was used to explore the correlation between characteristic genes and Estimate Score, which provided clues for clarifying the potential pathogenic mechanism of key genes. RESULTS: A total of 1,494 DEGs were identified from AML samples and normal samples, among which 1,181 genes were upregulated and 313 genes were downregulated in AML. There were 2 genes with a mean decrease Gini >2, namely, CDC20 and ESM1, respectively. The ROC curve showed that the area under the curve (AUC) of CDC20 was 0.966, and the 95% confidence interval (CI) was (0.939 to 0.987) (P<0.001). The AUC of ESM1 was 0.905, and 95% CI: 0.849 to 0.953 (P<0.001). Correlation analysis showed that CDC20 expression was negatively correlated with Estimate Score (R=−0.21, P=0.0036) in AML. The expression of ESM1 was negatively correlated with Estimate Score (R=−0.57, P<0.001). CONCLUSIONS: The genes CDC20 and ESM1 were identified as AML characteristic genes by random forest algorithm. Both CDC20 and ESM1 have good diagnostic efficacy for AML. They may play a carcinogenic role by promoting tumor cell proliferation and inhibiting immune cell chemotaxis, which are potential biological markers.
format Online
Article
Text
id pubmed-9273715
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-92737152022-07-13 Screening diagnostic markers for acute myeloid leukemia based on bioinformatics analysis Chen, Wenting Liu, Dan Wang, Guyun Pan, Yanping Wang, Shuwen Tang, Ruimei Transl Cancer Res Original Article BACKGROUND: An in-depth understanding of the key molecules and associated mechanisms involved in acute myeloid leukemia (AML) carcinogenesis, proliferation, and relapse is critical. This provides a basis for disease screening, early diagnosis, and development of effective treatment strategies and prognosis. METHODS: We downloaded AML transcription data sets from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Differentially expressed genes (DEGs) were screened by R software and limma packages. Gene Ontology (GO) functional enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed on DEGs by public databases. In the DEG set, a random forest algorithm was used to identify characteristic genes of AML. The receiver operator characteristic (ROC) curve was used to evaluate the diagnostic efficacy of selected characteristic genes, which provided clues for the discovery of early diagnostic markers. The Estimate score was calculated using the Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data (ESTIMATE) algorithm. Spearman’s correlation test was used to explore the correlation between characteristic genes and Estimate Score, which provided clues for clarifying the potential pathogenic mechanism of key genes. RESULTS: A total of 1,494 DEGs were identified from AML samples and normal samples, among which 1,181 genes were upregulated and 313 genes were downregulated in AML. There were 2 genes with a mean decrease Gini >2, namely, CDC20 and ESM1, respectively. The ROC curve showed that the area under the curve (AUC) of CDC20 was 0.966, and the 95% confidence interval (CI) was (0.939 to 0.987) (P<0.001). The AUC of ESM1 was 0.905, and 95% CI: 0.849 to 0.953 (P<0.001). Correlation analysis showed that CDC20 expression was negatively correlated with Estimate Score (R=−0.21, P=0.0036) in AML. The expression of ESM1 was negatively correlated with Estimate Score (R=−0.57, P<0.001). CONCLUSIONS: The genes CDC20 and ESM1 were identified as AML characteristic genes by random forest algorithm. Both CDC20 and ESM1 have good diagnostic efficacy for AML. They may play a carcinogenic role by promoting tumor cell proliferation and inhibiting immune cell chemotaxis, which are potential biological markers. AME Publishing Company 2022-06 /pmc/articles/PMC9273715/ /pubmed/35836534 http://dx.doi.org/10.21037/tcr-22-1257 Text en 2022 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Original Article
Chen, Wenting
Liu, Dan
Wang, Guyun
Pan, Yanping
Wang, Shuwen
Tang, Ruimei
Screening diagnostic markers for acute myeloid leukemia based on bioinformatics analysis
title Screening diagnostic markers for acute myeloid leukemia based on bioinformatics analysis
title_full Screening diagnostic markers for acute myeloid leukemia based on bioinformatics analysis
title_fullStr Screening diagnostic markers for acute myeloid leukemia based on bioinformatics analysis
title_full_unstemmed Screening diagnostic markers for acute myeloid leukemia based on bioinformatics analysis
title_short Screening diagnostic markers for acute myeloid leukemia based on bioinformatics analysis
title_sort screening diagnostic markers for acute myeloid leukemia based on bioinformatics analysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273715/
https://www.ncbi.nlm.nih.gov/pubmed/35836534
http://dx.doi.org/10.21037/tcr-22-1257
work_keys_str_mv AT chenwenting screeningdiagnosticmarkersforacutemyeloidleukemiabasedonbioinformaticsanalysis
AT liudan screeningdiagnosticmarkersforacutemyeloidleukemiabasedonbioinformaticsanalysis
AT wangguyun screeningdiagnosticmarkersforacutemyeloidleukemiabasedonbioinformaticsanalysis
AT panyanping screeningdiagnosticmarkersforacutemyeloidleukemiabasedonbioinformaticsanalysis
AT wangshuwen screeningdiagnosticmarkersforacutemyeloidleukemiabasedonbioinformaticsanalysis
AT tangruimei screeningdiagnosticmarkersforacutemyeloidleukemiabasedonbioinformaticsanalysis